Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the special report in accordance with article 7:228 of the Belgian Code of Companies and Associations, regarding the continuation of the business activities CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Approval of the continuation of the business activities CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the annual report of the Board of Directors regarding the fiscal year ended on 31 December 2024 CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the report of the statutory auditor AUDIT-RELATED ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Approval of the annual accounts for the fiscal year ended on 31 December 2024 CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Allocation of the results CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year AUDIT-RELATED ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the special report in accordance with article 7:228 of the Belgian Code of Companies and Associations, regarding the continuation of the business activities CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Approval of the continuation of the business activities CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the annual report of the Board of Directors regarding the fiscal year ended on 31 December 2024 CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Acknowledgment of the report of the statutory auditor AUDIT-RELATED ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Approval of the annual accounts for the fiscal year ended on 31 December 2024 CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Allocation of the results CORPORATE GOVERNANCE ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR Flamingo Therapeutics, Inc. 07/07/2025 Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year AUDIT-RELATED ISSUER 136337.000000 0.000000 FOR 136337.000000 FOR ProThera Limited 10/21/2025 To receivee and consider the Company's Financial Statements for the year ended 31 December 2023 and the reports of the Directors and Auditors on those Financial Statements AUDIT-RELATED ISSUER 194134.000000 0.000000 FOR 194134.000000 FOR ProThera Limited 10/21/2025 To review the Company's affairs CORPORATE GOVERNANCE ISSUER 194134.000000 0.000000 FOR 194134.000000 FOR ProThera Limited 10/21/2025 To re-appoint the Company statutory auditors to continue in office pursuant to section 383 of the Companies Act 2014 AUDIT-RELATED ISSUER 194134.000000 0.000000 FOR 194134.000000 FOR ProThera Limited 10/21/2025 To authorise the directors to approve the remuneration of the statutory auditors for the year ended 31 December 2024 AUDIT-RELATED ISSUER 194134.000000 0.000000 FOR 194134.000000 FOR ProThera Limited 10/21/2025 To adopt the Constitution of the Company in the form presented CORPORATE GOVERNANCE ISSUER 194134.000000 0.000000 FOR 194134.000000 FOR Alpha-9 Oncology Inc. 06/26/2026 Appointment of Auditor: Appointment of KPMG LLP of Boston, Massachusetts as auditors for the Company for the 2026 fiscal year and authorization of the directors to fix their remuneration AUDIT-RELATED ISSUER 2871748.000000 0.000000 FOR 2871748.000000 FOR Alpha-9 Oncology Inc. 06/26/2026 Number of Directors: Setting the number of directors of the Company at nine (9). CORPORATE GOVERNANCE ISSUER 2871748.000000 0.000000 FOR 2871748.000000 FOR Alpha-9 Oncology Inc. 06/26/2026 Election of Directors: Election of Shelley Chu, Melissa McCracken, Patrick Heron, Evan Rachlin, Matthew Young, Darcy Mootz, Jean-Jacques Bienaime, Steven Stein and Paul Blanchfield as directors of the Company, each to serve until the next annual meeting of the shareholders and until his or her respective successor is duly elected and qualified, or such director's earlier death, resignation or removal. DIRECTOR ELECTIONS ISSUER 2871748.000000 0.000000 FOR 2871748.000000 FOR Alpha-9 Oncology Inc. 06/26/2026 Amendment to Equity Incentive Plan - Preferred Majority Resolution: Ratification, confirmation and approval of the amendment and restatement of the Company's Third Amended and Restated Equity Incentive Plan (dated September 30, 2024), to clarify the aggregate number of Common shares issuable thereunder, as approved by the board of directors of the Company on November 9, 2025, and as set out in the Company's Fourth Amended and Restated Equity Incentive Plan dated November 9, 2025 and attached to the Circular as Schedule "B". COMPENSATION ISSUER 2871748.000000 0.000000 FOR 2871748.000000 FOR